This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
miLab Platform ProductsImprove diagnostic workflows
Improve diagnostic workflows
and accessibility at once
Beyond DiagnosticsWe provide products and services that impact
We provide products and services that impact
one billion people's life in the world.
Noul focuses on the most challenging healthcare issues the world has yet to resolve.
We deliver innovative diagnostic solutions in blood and tissue diagnostics dramatically improve medical access and
conquer cancer.
Our Story in Numbers
- NVIDIA GTC selected AI Startups
- Top 0
- Cumulative investment (USD)
- 0million
- Annual sales growth (as of 2023)
- 0%
We continues to grow, moving toward the next stage.
- Patent registrations and applications
- 0cases, 0cases
- Cumulative orders for National R&D project (USD)
- 0million
- Researcher in company
- 0%
We creates innovation based on R&D and technology patents.
- Countries using miLab™
- 0countries
- Cumulative diagnosis using miLab™
- 0diagnoses
- Partner organizations
- 0+
miLab™ Solution leads the global blood and cancer diagnosis.
- Digitalize entire process (stain, scan, AI analyze)
- All inOne
- Time required for diagnosis (more than 2x improvement)
- Avg0mins
- Accuracy of test results (Labcorp clinical trial - miLab™ MAL)
- Sensitivity0% ,
Specificity0%
miLab™ Solution has dramatically improved the diagnostic process.
Noul Highlights
Find our latest news
View More-
Transforming Diagnostics: The Rise of AI in Healthcare Innovation Table of Contents Toggle AI Guiding the Future of DiagnosticsNoul’s AI-Powered… Read MoreBlog | 2025.10.30
-
[Press Release] Noul Supplies AI Diagnostic Platform miLab™ to Charité, Europe’s Leading University Hospital Yongin, Republic of Korea – October 28, 2025 – Noul Co., Ltd.(CEO David Lim), an AI-driven blood and cancer diagnostics company, announced the supply of its AI-based malaria diagnostic solution miLab™ MAL to Charité – Universitätsmedizin Berlin, Germany’s largest and most prestigious university hospital. Founded over 300 years… Read MoreNews | 2025.10.28
-
WHO’s Malaria Resurgence Prevention Guidance: Purpose and Significance Table of Contents Toggle Malaria-Free Countries and Elimination StrategiesRisk Factors for… Read MoreBlog | 2025.10.16
-
AI-Powered Diagnostics Gain Momentum in Brazil’s Fight Against Cervical Cancer Table of Contents Toggle Cervical Cancer: The Third Most Common Cancer Among Women… Read MoreBlog | 2025.09.25
-
[Press Release] Noul Secures FDA Registration for Cervical Cancer Diagnostic Cartridge September 23, 2025 – Yongin, Republic of Korea – Noul Co., Ltd. (CEO: David Lim), a medical AI company specializing in blood and cancer diagnostics, announced that FDA registration has been completed for its cervical cancer diagnostic cartridge miLab™ Cartridge CER and clearing agent SafeFix™ CER, both core components… Read MoreNews | 2025.09.23
-
On-Site CBC & Blood Morphology: Enhancing Diagnostic Accuracy and Speed Table of Contents Toggle Digital Automated Blood Testing Platform Enhancing Diagnostic Efficiency… Read MoreBlog | 2025.09.11
- Career Join our team, committed to
making a positive impact - View More
- Sustainability at Noul Sustainability is
at the core of our business philosophy. - Sustainability
